Evidence-based practices need to beware of experts.

P. Corrigan

DOI: https://doi.org/10.1176/APPI.PS.53.8.1031-A

2002-08-01

Psychiatric Services

Abstract:

What problem does this paper attempt to address?

Evidence of Accelerated Epigenetic Aging of Breast Tissues in Patients with Breast Cancer is Driven by CpGs Associated with Polycomb Related Genes

Rozenblit Mariya,Hofstatter Erin,Liu Zuyun,O’Meara Tess,Storniolo Anna Maria,Dalela Disha,Singh Vineet,Pusztai Lajos,Levine Morgan

DOI: https://doi.org/10.1186/s13148-022-01249-z

2022-01-01

Clinical Epigenetics

Abstract:Purpose: Age is one of the strongest risk factors for the development of breast cancer, however the underlying etiology linking age and breast cancer remains unclear. We have previously observed links between epigenetic aging signatures in breast/tumor tissue and breast cancer risk/prevalence. However, these DNA methylation-based aging biomarkers capture diverse epigenetic phenomena and it is not known to what degree they relate to breast cancer risk, and/or progression. Methods: Using six epigenetic clocks, we analyzed whether they distinguish normal breast tissue adjacent to tumor (cases) vs normal breast tissue from healthy controls (controls). Results: The Levine (p=0.0037) and Yang clocks (p=0.023) showed significant epigenetic age acceleration in cases vs controls in breast tissue. We observed that much of the difference between cases and controls is driven by CpGs associated with polycomb related genes. Thus, we developed a new score utilizing only CpGs associated with polycomb related genes and demonstrated that it robustly captured epigenetic age acceleration in cases vs controls (p=0.00012). Finally, we tested whether this same signal could be seen in peripheral blood. We observed no difference in cases vs. controls and no correlation between matched tissue/blood samples, suggesting that peripheral blood is not a good surrogate marker for epigenetic age acceleration. Conclusions: Moving forward, it will be critical for studies to elucidate whether epigenetic age acceleration in breast tissue precedes breast cancer diagnosis and whether methylation changes at CpGs associated with polycomb related genes can be used to assess the risk of developing breast cancer among unaffected individuals.
Abstract 7005: Distinct DNA methylation patterns between early-onset and average-onset colorectal cancer patients

L. Joseph Su,Ping-Ching Hsu,Aniruddha Rathod,Yulun Liu,Jacopo Ferruzzi,Syed Kazmi,Emina Huang

DOI: https://doi.org/10.1158/1538-7445.am2024-7005

IF: 11.2

2024-03-24

Cancer Research

Abstract:Objective: Early onset colorectal cancer (EO CRC) is rising at an alarming rate. While average onset colorectal cancer (AO CRC) affects patients mostly above 65 years of age, EO CRC affects patients under 50 years of age, disproportionately affecting males from low-income communities and racial/ethnic minorities. Chronic inflammation has been identified as a strong contributor to pathogenesis. We hypothesize that methylation of DNA may serve as a potential mechanism associated with chronic inflammation that contributes to the etiology differentially between EO and AO CRC. Methods: Formalin-fixed paraffin-embedded (FFPE) tissue specimens from four AO and EO CRC patients each were retrieved from the Tissue Repository. Paraffin curls containing tumor and adjacent normal tissues were generated from appropriate EO and AO CRC patient tissues. The Qiagen GeneRead DNA FFPE genomic DNA kit was then used to extract the DNA from the paraffin curls. Illumina Methylation EPIC v2.0 kit was used to evaluate DNA methylation (DNAm) patterns after the restoration process from deamination in the fixed/embedded sample using the Uracil-N-Glycosylase enzyme. Unreliable and non-specific probes were removed before statistical analysis for differentially methylated CpG sites. Age acceleration for each tissue was calculated by comparing the estimated DNAm age with chronological age using the Horvath approach. Results: A clear clustering of DNAm patterns by age of onset were observed for both normal and tumor tissues. However, there was no difference when comparing tumor and normal tissues after multiple corrections. Four-way ANCOVA adjusting for race, gender, BMI, and tissue type suggested that age onset was the most significant factor. We also found that age acceleration in EO CRC tissue is greater than in AO CRC. After applying Bonferroni correction, significant differentially methylated regions (DMRs) were found in the promoter and the gene body of SNTB1, NFATC3, SLC25A24, RABGAP1L, WDSUB1, WWOX, SELB, SLC28A3, and PPP6R2 in EO CRC patients when compared to AO CRC. SNTB1 regulates colorectal cancer progression and stemness, while NFATC3 has been associated with inflammation and cancer. Conclusions: The preliminary results from this study showed a significant difference in the DNAm profile of FFPE samples between AO and EO CRC. The finding suggests that epigenetics may play a role in the etiology of CRC, potentially involved in the chronic inflammation pathway. The analysis of a larger patient number is underway to strengthen these findings. Citation Format: L. Joseph Su, Ping-Ching Hsu, Aniruddha Rathod, Yulun Liu, Jacopo Ferruzzi, Syed Kazmi, Emina Huang. Distinct DNA methylation patterns between early-onset and average-onset colorectal cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7005.

oncology
Abstract P2-09-02: Evidence of Accelerated Epigenetic Aging of Breast Tissues in Patients with Breast Cancer Compared to Women Without Cancer

Erin Hofstatter,Morgan Levine,Zuyun Liu,Tess O'Meara,Disha Dalela,Lajos Pusztai

DOI: https://doi.org/10.1158/1538-7445.sabcs19-p2-09-02

IF: 11.2

2020-01-01

Cancer Research

Abstract:Abstract Background: Age is the largest risk factor for breast cancer development. Faster biological aging, particularly in breast tissue, may predispose women to higher risk of developing breast cancer. Recently, a set of promising biomarkers of aging, called “epigenetic clocks” (also referred to as “epigenetic age”) have been developed to estimate aging rates in tissues and cells. Using one of the original epigenetic clocks based on DNA methylation patterns, we previously demonstrated that normal breast tissue from luminal breast cancer patients exhibited accelerated aging compared to patients without breast cancer. Here we test whether incorporation of nearly a dozen epigenetic clocks, each capturing slightly different biological aging phenomena, can consistently distinguish normal breast tissue from cancer patients versus healthy controls. We also examined concordance between epigenetic age assessment from paired breast tissue and peripheral blood mononuclear cells. Methods: We examined 282 specimens including DNA from 94 normal breast tissues (41 from patients with breast cancer, and 53 from non-cancer controls) and 188 blood samples (97 from breast cancer, and 91 from controls). DNA methylation was assessed via the Illumina HumanMethylation450k and HumanMethylationEPIC BeadChip for both tissue and blood samples, and 11 epigenetic clocks were calculated following published methods. Associations of these clocks with breast cancer were examined using logistic regression models and Receiver Operating Characteristics (ROC) curves to determine predictive power in distinguishing samples from cancer patients versus healthy controls. Results: After accounting for chronological age, we observed increases in most epigenetic clocks for cancer patients compared to normal samples from controls, which indicates accelerated epigenetic aging (e.g., Zhang clock in tissue, 0.55 vs. -0.42; in blood, 0.10 vs. -0.20, all P<0.05). When including age, Zhang clock showed the best predictive power of breast cancer in tissues (Area Under The Curve [AUC] =0.79, 95% Confidence Interval [CI]: 0.69, 0.87) and including all clocks further improved the predictive power (AUC=0.89, 95% CI: 0.83, 0.95). However, all clocks exhibited moderate predictive powers in blood (all AUC<0.7), even when combining them together (AUC=0.70, 95% CI: 0.62, 0.77). In 80 participants with both tissue and blood samples, we observed highest concordance for Hannum clock (bicor=0.43) and lowest concordance for Zhang clock (bicor =-0.19). Conclusions: Epigenetic aging-based biomarkers distinguish non-tumor breast tissues of patients with breast cancer from breast tissues of healthy controls. These findings raise the possibility that epigenetic markers assessed on needle biopsies of the breast might identify individuals at risk for developing breast cancer. Citation Format: Erin Hofstatter, Morgan Levine, Zuyun Liu, Tess O'Meara, Disha Dalela, Lajos Pusztai. Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer compared to women without cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-09-02.
Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer

Simeng Gu,Shujuan Lin,Ding Ye,Sangni Qian,Danjie Jiang,Xiaocong Zhang,Qilong Li,Jinhua Yang,Xiaojiang Ying,Zhenjun Li,Mengling Tang,Jianbing Wang,Mingjuan Jin,Kun Chen

DOI: https://doi.org/10.1186/s13148-019-0628-y

2019-01-01

Clinical Epigenetics

Abstract:Background Epigenetic alternation is a common contributing factor to neoplastic transformation. Although previous studies have reported a cluster of aberrant promoter methylation changes associated with silencing of tumor suppressor genes, little is known concerning their sequential DNA methylation changes during the carcinogenetic process. The aim of the present study was to address a genome-wide search for identifying potentially important methylated changes and investigate the onset and pattern of methylation changes during the progression of colorectal neoplasia. Methods A three-phase design was employed in this study. In the screening phase, DNA methylation profile of 12 pairs of colorectal cancer (CRC) and adjacent normal tissues was analyzed by using the Illumina MethylationEPIC BeadChip. Significant CpG sites were selected based on a cross-validation analysis from The Cancer Genome Atlas (TCGA) database. Methylation levels of candidate CpGs were assessed using pyrosequencing in the training dataset (tumor lesions and adjacent normal tissues from 46 CRCs) and the validation dataset (tumor lesions and paired normal tissues from 13 hyperplastic polyps, 129 adenomas, and 256 CRCs). A linear mixed-effects model was used to examine the incremental changes of DNA methylation during the progression of colorectal neoplasia. Results The comparisons between normal and tumor samples in the screening phase revealed an extensive CRC-specific methylomic pattern with 174,006 (21%) methylated CpG sites, of which 22,232 (13%) were hyermethylated and 151,774 (87%) were hypomethylated. Hypermethylation mostly occurred in CpG islands with an overlap of gene promoters, while hypomethylation tended to be mapped far away from functional regions. Further cross validation analysis from TCGA dataset confirmed 265 hypermethylated promoters coupling with downregulated gene expression. Among which, hypermethylated changes in MEEPD2 promoter was successfully replicated in both training and validation phase. Significant hypermethylation appeared since precursor lesions with an extensive modification in CRCs. The linear mixed-effects modeling analysis found that a cumulative pattern of MPPED2 methylation changes from normal mucosa to hyperplastic polyp to adenoma, and to carcinoma ( P < 0.001). Conclusions Our findings indicate that epigenetic alterations of MPPED2 promoter region appear sequentially during the colorectal neoplastic progression. It might be able to serve as a promising biomarker for early diagnosis and stage surveillance of colorectal tumorigenesis.
Aging related methylation influences the gene expression of key control genes in colorectal cancer and adenoma

Orsolya Galamb,Alexandra Kalmár,Barbara Kinga Barták,Árpád V Patai,Katalin Leiszter,Bálint Péterfia,Barnabás Wichmann,Gábor Valcz,Gábor Veres,Zsolt Tulassay,Béla Molnár

DOI: https://doi.org/10.3748/wjg.v22.i47.10325

IF: 5.374

2016-01-01

World Journal of Gastroenterology

Abstract:AIM: To analyze colorectal carcinogenesis and age-related DNA methylation alterations of gene sequences associated with epigenetic clock CpG sites.METHODS: In silico DNA methylation analysis of 353 epigenetic clock CpG sites published by Steve Horvath was performed using methylation array data for a set of 123 colonic tissue samples [64 colorectal cancer (CRC), 42 adenoma, 17 normal; GEO accession number: GSE48684]. Among the differentially methylated age-related genes, secreted frizzled related protein 1 (SFRP1) promoter methylation was further investigated in colonic tissue from 8 healthy adults, 19 normal children, 20 adenoma and 8 CRC patients using bisulfite-specific PCR followed by methylation-specific high resolution melting (MS-HRM) analysis. mRNA expression of age-related "epigenetic clock" genes was studied using Affymetrix HGU133 Plus2.0 whole transcriptome data of 153 colonic biopsy samples (49 healthy adult, 49 adenoma, 49 CRC, 6 healthy children) (GEO accession numbers: GSE37364, GSE10714, GSE4183, GSE37267). Whole promoter methylation analysis of genes showing inverse DNA methylation-gene expression data was performed on 30 colonic samples using methyl capture sequencing.RESULTS: Fifty-seven age-related CpG sites including hypermethylated PPP1R16B, SFRP1, SYNE1 and hypomethylated MGP, PIPOX were differentially methylated between CRC and normal tissues (P < 0.05, Δβ ≥ 10%). In the adenoma vs normal comparison, 70 CpG sites differed significantly, including hypermethylated DKK3, SDC2, SFRP1, SYNE1 and hypomethylated CEMIP, SPATA18 (P < 0.05, Δβ ≥ 10%). In MS-HRM analysis, the SFRP1 promoter region was significantly hypermethylated in CRC (55.0% ± 8.4 %) and adenoma tissue samples (49.9% ± 18.1%) compared to normal adult (5.2% ± 2.7%) and young (2.2% ± 0.7%) colonic tissue (P < 0.0001). DNA methylation of SFRP1 promoter was slightly, but significantly increased in healthy adults compared to normal young samples (P < 0.02). This correlated with significantly increased SFRP1 mRNA levels in children compared to normal adult samples (P < 0.05). In CRC tissue the mRNA expression of 117 age-related genes were changed, while in adenoma samples 102 genes showed differential expression compared with normal colonic tissue (P < 0.05, logFC > 0.5). The change of expression for several genes including SYNE1, CLEC3B, LTBP3 and SFRP1, followed the same pattern in aging and carcinogenesis, though not for all genes (e.g., MGP).CONCLUSION: Several age-related DNA methylation alterations can be observed during CRC development and progression affecting the mRNA expression of certain CRC- and adenoma-related key control genes.

gastroenterology & hepatology
Abstract 7017: Increased epigenetic age acceleration in young adult and early onset colorectal cancer patients post-treatment: A ColoCare Pilot Study

Erin M. Siegel,Jacob K. Kresovich,Amanda M. Bloomer,Anders Berglund,Esther Jean-Baptiste,Gillian Trujillo,Rachel Carmella,Julaxis Love,Seth Felder,Jennifer Ose,Biljana Gigic,Christopher I. Li,Jane C. Figueiredo,Adetunji T. Toriola,Cornelia M. Ulrich,David Shibata,Laura B. Oswald

DOI: https://doi.org/10.1158/1538-7445.am2024-7017

IF: 11.2

2024-03-23

Cancer Research

Abstract:Introduction: Advanced biological age relative to chronological age has been observed in individuals with colorectal cancer (CRC), and there is growing evidence that cancer treatments can further accelerate biological aging. However, the influence of age at diagnosis on these relationships has yet to be examined in detail. This pilot study used data from the ColoCare Study to explore pre- and post-treatment differences in age acceleration by chronological age at CRC diagnosis. Methods: The ColoCare Study is a prospective cohort study of newly-diagnosed CRC patients enrolled across seven U.S. and European sites. Participants in this pilot study were from the ColoCare site in Tampa, Florida who had available pre-treatment blood DNA. Young adult (YA, aged 18-39) and early onset (EO, aged 40-49) participants were matched with average onset (AO, aged 50-64) and late onset (LO, aged >64) participants on stage, sex, race and microsatellite instability status. Genome-wide DNA methylation profiles were assayed on buffy coat DNA using MethylationEPIC v2 BeadChips. PhenoAgeAccel and GrimAgeAccel were calculated on all samples to quantify the difference between DNA methylation-predicted biological age and chronological age (i.e., age acceleration). Linear regression models were used to estimate the associations of age at diagnosis and treatment with PhenoAgeAccel and GrimAgeAccel, adjusted for sex, race, and site (rectal, colon). Results: The sample (n=60) included n=19 YA, n=15 EO, n=11 AO, and n=15 LO participants with pre-treatment blood DNA. Over half (n=15 YA/EO, n=20 AO/LO) had a paired post-treatment blood sample available. Half of participants were female and had colon tumors, and 76% were diagnosed with stage I-III disease. Pre-treatment, PhenoAgeAccel and GrimAgeAccel were similar across age groups (P > 0.05). In the subset of participants with pre- and post-treatment samples, age acceleration appeared to increase post-treatment (pre- and post-treatment differences, PhenoAgeAccel: 1.44, SD: 5.55, P= 0.13; GrimAgeAccel: 0.92, SD: 2.80, P= 0.06). Increases were largest among YA/EO participants. In adjusted models, the predicted differences in pre-to post-treatment PhenoAgeAccel were 2.89 (95% CI: -0.13, 5.90) in YA/EO and 0.36 (95% CI: -2.25, 2.96) in AO/LO (P-difference= 0.20). The predicted differences in GrimAgeAccel were 1.75 (95% CI: 0.25, 3.25) in YA/EO and 0.30 (95% CI: -1.00, 1.60) in AO/LO (P-difference= 0.15). Conclusions: In this pilot study of CRC patients, pre-treatment age acceleration did not vary by age at diagnosis. Post-treatment, patients diagnosed at age 49 or younger had larger increases in age acceleration than patients diagnosed at age 50 or older. These findings warrant further investigation in larger samples and to determine if increases in post-treatment age acceleration as associated with patient outcomes and treatment response. Citation Format: Erin M. Siegel, Jacob K. Kresovich, Amanda M. Bloomer, Anders Berglund, Esther Jean-Baptiste, Gillian Trujillo, Rachel Carmella, Julaxis Love, Seth Felder, Jennifer Ose, Biljana Gigic, Christopher I. Li, Jane C. Figueiredo, Adetunji T. Toriola, Cornelia M. Ulrich, David Shibata, Laura B. Oswald. Increased epigenetic age acceleration in young adult and early onset colorectal cancer patients post-treatment: A ColoCare Pilot Study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7017.

oncology
DNA methylation age as a biomarker for cancer

Chung‐Ho E. Lau,Oliver Robinson

DOI: https://doi.org/10.1002/ijc.33451

2021-01-09

International Journal of Cancer

Abstract:Cancer is well established as an age‐associated disease, and there is substantial overlap in the molecular, cellular and physiological changes observed with both ageing and the progression of cancer. Age‐specific declines in resilience mechanisms such as DNA repair or epigenetic maintenance may contribute to the development of cancer. These declines may be assessed through biomarkers that measure biological age and through the related concept of "age acceleration". Epigenetic clocks, assessed through DNA methylation levels, are among the most widely used biological age markers in cancer studies. In this review, we discuss the use of DNA methylation ageing measures to predict population cancer incidence, mortality and survival. Blood‐based DNA methylation age estimators appear to be promising measures of increased cancer risk and mortality, although their reported effects are generally weak, thus its clinical relevance remains to be validated in large case‐cohort and longitudinal studies. Future development of epigenetic and other biological age biomarkers will likely further elucidate the links between ageing and cancer.This article is protected by copyright. All rights reserved.

oncology
Epigenetic age acceleration of cervical squamous cell carcinoma converged to human papillomavirus 16/18 expression, immunoactivation, and favourable prognosis

Xiaofan Lu,Yujie Zhou,Jialin Meng,Liyun Jiang,Jun Gao,Xiaole Fan,Yanfeng Chen,Yu Cheng,Yang Wang,Bing Zhang,Hangyu Yan,Fangrong Yan

DOI: https://doi.org/10.1186/s13148-020-0822-y

2020-02-10

Abstract:Background: Ageing-associated molecular changes have been assumed to trigger malignant transformations and the epigenetic clock, and the DNA methylation age has been shown to be highly correlated with chronological age. However, the associations between the epigenetic clock and cervical squamous cell carcinoma (CSCC) prognosis, other molecular characteristics, and clinicopathological features have not been systematically investigated. To this end, we computed the DNA methylation (DNAm) age of 252 CSCC patients and 200 normal samples from TCGA and three external cohorts by using the Horvath clock model. We characterized the differences in human papillomavirus (HPV) 16/18 expression, pathway activity, genomic alteration, and chemosensitivity between two DNAm age subgroups. We then used Cox proportional hazards regression and restricted cubic spline (RCS) analysis to assess the prognostic value of epigenetic acceleration. Results: DNAm age was significantly associated with chronological age, but it was differentiated between tumour and normal tissue (P < 0.001). Two DNAm age groups, i.e. DNAmAge-ACC and DNAmAge-DEC, were identified; the former had high expression of the E6/E7 oncoproteins of HPV16/18 (P < 0.05), an immunoactive phenotype (all FDRs < 0.05 in enrichment analysis), CpG island hypermethylation (P < 0.001), and lower mutation load (P = 0.011), including for TP53 (P = 0.002). When adjusted for chronological age and tumour stage, every 10-year increase in DNAm age was associated with a 12% decrease in fatality (HR 0.88, 95% CI 0.78-0.99, P = 0.03); DNAmAge-ACC had a 41% lower mortality risk and 47% lower progression rate than DNAmAge-DEC and was more likely to benefit from chemotherapy. RCS revealed a positive non-linear association between DNAm age and both mortality and progression risk (both, P < 0.05). Conclusions: DNAm age is an independent predictor of CSCC prognosis. Better prognosis, overexpression of HPV E6/E7 oncoproteins, and higher enrichment of immune signatures were observed in DNAmAge-ACC tumours.
Genomic landscape of diploid and aneuploid microsatellite stable early onset colorectal cancer

Yumei Zhou,Xianfeng Chen,Jun Chen,Conner D. Kendrick,Ramesh K. Ramanathan,Rondell P. Graham,Kimberlee F. Kossick,Lisa A. Boardman,Michael T. Barrett

DOI: https://doi.org/10.1038/s41598-024-59398-5

IF: 4.6

2024-04-24

Scientific Reports

Abstract:Although colorectal cancer (CRC) remains the second leading cause of cancer-related death in the United States, the overall incidence and mortality from the disease have declined in recent decades. In contrast, there has been a steady increase in the incidence of CRC in individuals under 50 years of age. Hereditary syndromes contribute disproportionately to early onset CRC (EOCRC). These include microsatellite instability high (MSI+) tumors arising in patients with Lynch Syndrome. However, most EOCRCs are not associated with familial syndromes or MSI+ genotypes. Comprehensive genomic profiling has provided the basis of improved more personalized treatments for older CRC patients. However, less is known about the basis of sporadic EOCRC. To define the genomic landscape of EOCRC we used DNA content flow sorting to isolate diploid and aneuploid tumor fractions from 21 non-hereditary cases. We then generated whole exome mutational profiles for each case and whole genome copy number, telomere length, and EGFR immunohistochemistry (IHC) analyses on subsets of samples. These results discriminate the molecular features of diploid and aneuploid EOCRC and provide a basis for larger population-based studies and the development of effective strategies to monitor and treat this emerging disease.

multidisciplinary sciences
Tumor Long Interspersed Nucleotide Element-1 (LINE-1) Hypomethylation in Relation to Age of Colorectal Cancer Diagnosis and Prognosis

Naohiko Akimoto,Melissa Zhao,Tomotaka Ugai,Rong Zhong,Mai Chan Lau,Kenji Fujiyoshi,Junko Kishikawa,Koichiro Haruki,Kota Arima,Tyler S. Twombly,Xuehong Zhang,Edward L. Giovannucci,Kana Wu,Mingyang Song,Andrew T. Chan,Yin Cao,Jeffrey A. Meyerhardt,Kimmie Ng,Marios Giannakis,Juha P. Väyrynen,Jonathan A. Nowak,Shuji Ogino

DOI: https://doi.org/10.3390/cancers13092016

2021-04-22

Cancers

Abstract:Evidence indicates the pathogenic role of epigenetic alterations in early-onset colorectal cancers diagnosed before age 50. However, features of colorectal cancers diagnosed at age 50–54 (hereafter referred to as “intermediate-onset”) remain less known. We hypothesized that tumor long interspersed nucleotide element-1 (LINE-1) hypomethylation might be increasingly more common with decreasing age of colorectal cancer diagnosis. In 1356 colorectal cancers, including 28 early-onset and 66 intermediate-onset cases, the tumor LINE-1 methylation level measured by bisulfite-PCR-pyrosequencing (scaled 0 to 100) showed a mean of 63.6 (standard deviation (SD) 10.1). The mean tumor LINE-1 methylation level decreased with decreasing age (mean 64.7 (SD 10.4) in age ≥70, 62.8 (SD 9.4) in age 55–69, 61.0 (SD 10.2) in age 50–54, and 58.9 (SD 12.0) in age <50; p < 0.0001). In linear regression analysis, the multivariable-adjusted β coefficient (95% confidence interval (CI)) (vs. age ≥70) was −1.38 (−2.47 to −0.30) for age 55–69, −2.82 (−5.29 to −0.34) for age 50–54, and −4.54 (−8.24 to −0.85) for age 65) were 2.33 (1.49–3.64), 1.39 (1.05–1.85), and 1.29 (1.02–1.63), respectively (Ptrend = 0.0005). In conclusion, tumor LINE-1 hypomethylation is increasingly more common with decreasing age of colorectal cancer diagnosis, suggesting a role of global DNA hypomethylation in colorectal cancer arising in younger adults.

oncology
DNA methylation-based biological aging and cancer risk and survival: Pooled analysis of seven prospective studies

Pierre-Antoine Dugué,Julie K Bassett,JiHoon E Joo,Chol-Hee Jung,Ee Ming Wong,Margarita Moreno-Betancur,Daniel Schmidt,Enes Makalic,Shuai Li,Gianluca Severi,Allison M Hodge,Daniel D Buchanan,Dallas R English,John L Hopper,Melissa C Southey,Graham G Giles,Roger L Milne

DOI: https://doi.org/10.1002/ijc.31189

2018-04-15

Abstract:The association between aging and cancer is complex. Recent studies have developed measures of biological aging based on DNA methylation and called them "age acceleration." We aimed to assess the associations of age acceleration with risk of and survival from seven common cancers. Seven case-control studies of DNA methylation and colorectal, gastric, kidney, lung, prostate and urothelial cancer and B-cell lymphoma nested in the Melbourne Collaborative Cohort Study were conducted. Cancer cases, vital status and cause of death were ascertained through linkage with cancer and death registries. Conditional logistic regression and Cox models were used to estimate odds ratios (OR) and hazard ratios (HR) and 95% confidence intervals (CI) for associations of five age acceleration measures derived from the Human Methylation 450 K Beadchip assay with cancer risk (N = 3,216 cases) and survival (N = 1,726 deaths), respectively. Epigenetic aging was associated with increased cancer risk, ranging from 4% to 9% per five-year age acceleration for the 5 measures considered. Heterogeneity by study was observed, with stronger associations for risk of kidney cancer and B-cell lymphoma. An associated increased risk of death following cancer diagnosis ranged from 2% to 6% per five-year age acceleration, with no evidence of heterogeneity by cancer site. Cancer risk and mortality were increased by 15-30% for the fourth versus first quartile of age acceleration. DNA methylation-based measures of biological aging are associated with increased cancer risk and shorter cancer survival, independently of major health risk factors.
DNA Methylation Age in Paired Tumor and Adjacent Normal Breast Tissue in Chinese Women with Breast Cancer

Hela Koka,Clara Bodelon,Steve Horvath,Priscilla Ming Yi Lee,Difei Wang,Lei Song,Tongwu Zhang,Amber N. Hurson,Jennifer Lyn Guida,Bin Zhu,Maeve Bailey-Whyte,Feng Wang,Cherry Wu,Koon Ho Tsang,Yee-Kei Tsoi,W. C. Chan,Sze Hong Law,Ray Ka Wai Hung,Gary M. Tse,Karen Ka-wan Yuen,Eric Karlins,Kristine Jones,Aurelie Vogt,Amy Hutchinson,Belynda Hicks,Montserrat Garcia-Closas,Stephen Chanock,Jill Barnholtz-Sloan,Lap Ah Tse,Xiaohong R. Yang

DOI: https://doi.org/10.1186/s13148-023-01465-1

2023-01-01

Clinical Epigenetics

Abstract:Abstract Background Few studies have examined epigenetic age acceleration (AA), the difference between DNA methylation (DNAm) predicted age and chronological age, in relation to somatic genomic features in paired cancer and normal tissue, with less work done in non-European populations. In this study, we aimed to examine DNAm age and its associations with breast cancer risk factors, subtypes, somatic genomic profiles including mutation and copy number alterations and other aging markers in breast tissue of Chinese breast cancer (BC) patients from Hong Kong. Methods We performed genome-wide DNA methylation profiling of 196 tumor and 188 paired adjacent normal tissue collected from Chinese BC patients in Hong Kong (HKBC) using Illumina MethylationEPIC array. The DNAm age was calculated using Horvath’s pan-tissue clock model. Somatic genomic features were based on data from RNA sequencing (RNASeq), whole-exome sequencing (WES), and whole-genome sequencing (WGS). Pearson’s correlation (r), Kruskal–Wallis test, and regression models were used to estimate associations of DNAm AA with somatic features and breast cancer risk factors. Results DNAm age showed a stronger correlation with chronological age in normal (Pearson r = 0.78, P < 2.2e−16) than in tumor tissue (Pearson r = 0.31, P = 7.8e−06). Although overall DNAm age or AA did not vary significantly by tissue within the same individual, luminal A tumors exhibited increased DNAm AA (P = 0.004) while HER2-enriched/basal-like tumors exhibited markedly lower DNAm AA (P = < .0001) compared with paired normal tissue. Consistent with the subtype association, tumor DNAm AA was positively correlated with ESR1 (Pearson r = 0.39, P = 6.3e−06) and PGR (Pearson r = 0.36, P = 2.4e−05) gene expression. In line with this, we found that increasing DNAm AA was associated with higher body mass index (P = 0.039) and earlier age at menarche (P = 0.035), factors that are related to cumulative exposure to estrogen. In contrast, variables indicating extensive genomic instability, such as TP53 somatic mutations, high tumor mutation/copy number alteration burden, and homologous repair deficiency were associated with lower DNAm AA. Conclusions Our findings provide additional insights into the complexity of breast tissue aging that is associated with the interaction of hormonal, genomic, and epigenetic mechanisms in an East Asian population.
Epigenome-wide Gene–age Interaction Analysis Reveals Reversed Effects of PRODH DNA Methylation on Survival Between Young and Elderly Early-Stage NSCLC Patients

Chao Chen,Yongyue Wei,Liangmin Wei,Jiajin Chen,Xin Chen,Xuesi Dong,Jieyu He,Lijuan Lin,Ying Zhu,Hui Huang,Dongfang You,Linjing Lai,Sipeng Shen,Weiwei Duan,Li Su,Andrea Shafer,Thomas Fleischer,Maria Moksnes Bjaanaes,Anna Karlsson,Maria Planck,Rui Wang,Johan Staaf,Aslaug Helland,Manel Esteller,Ruyang Zhang,Feng Chen,David C. Christiani

DOI: https://doi.org/10.18632/aging.103284

2020-01-01

Aging

Abstract:DNA methylation changes during aging, but it remains unclear whether the effect of DNA methylation on lung cancer survival varies with age. Such an effect could decrease prediction accuracy and treatment efficacy. We performed a methylation-age interaction analysis using 1,230 early-stage lung adenocarcinoma patients from five cohorts. A Cox proportional hazards model was used to investigate lung adenocarcinoma and squamous cell carcinoma patients for methylation-age interactions, which were further confirmed in a validation phase. We identified one adenocarcinoma-specific CpG probe, cg14326354(PRODH), with effects significantly modified by age (HRinteraction = 0.989; 95% CI: 0.986-0.994; P = 9.18x10-7). The effect of low methylation was reversed for young and elderly patients categorized by the boundary of 95% CI standard (HRyoung = 2.44; 95% CI: 1.26-4.72; P = 8.34x10-3; HRelderly = 0.58; 95% CI: 0.42-0.82; P = 1.67x10-3). Moreover, there was an antagonistic interaction between low cg14326354(PRODH) methylation and elderly age (HRinteraction = 0.21; 95% CI: 0.11-0.40; P = 2.20x10-6). In summary, low methylation of cg14326354PRODH might benefit survival of elderly lung adenocarcinoma patients, providing new insight to age-specific prediction and potential drug targeting.
Exploring the DNA methylome of Korean patients with colorectal cancer consolidates the clinical implications of cancer-associated methylation markers

Sejoon Lee,Kil-yong Lee,Ji-Hwan Park,Duck-Woo Kim,Heung-Kwon Oh,Seong-Taek Oh,Jongbum Jeon,Dongyoon Lee,Soobok Joe,Hoang Bao Khanh Chu,Jisun Kang,Jin-Young Lee,Sheehyun Cho,Hyeran Shim,Si-Cho Kim,Hong Seok Lee,Young-Joon Kim,Jin Ok Yang,Jaeim Lee,Sung-Bum Kang

DOI: https://doi.org/10.5483/bmbrep.2023-0103

2024-03-12

BMB Reports

Abstract:Aberrant DNA methylation plays a critical role in the development and progression of colorectal cancer (CRC), which has high incidence and mortality rates in Korea. Various CRC-associated methylation markers for cancer diagnosis and prognosis have been developed; however, they have not been validated for Korean patients owing to the lack of comprehensive clinical and methylome data. Here, we obtained reliable methylation profiles for 228 tumor, 103 adjacent normal, and two unmatched normal colon tissues from Korean patients with CRC using an Illumina Infinium EPIC array; the data were corrected for biological and experiment biases. A comparative methylome analysis confirmed the previous findings that hypermethylated positions in the tumor were highly enriched in CpG island and promoter, 5' untranslated, and first exon regions. However, hypomethylated positions were enriched in the open-sea regions considerably distant from CpG islands. After applying a CpG island methylator phenotype (CIMP) to the methylome data of tumor samples to stratify the CRC patients, we consolidated the previously established clinicopathological findings that the tumors with high CIMP signatures were significantly enriched in the right colon. The results showed a higher prevalence of microsatellite instability status and MLH1 methylation in tumors with high CMP signatures than in those with low or non-CIMP signatures. Therefore, our methylome analysis and dataset provide insights into applying CRC-associated methylation markers for Korean patients regarding cancer diagnosis and prognosis. [BMB Reports 2024; 57(3): 161-166].

biochemistry & molecular biology
Single-channel properties of the nonselective cation conductance induced by neurotensin in dopaminergic neurons.

P. Chien,R. Farkas,S. Nakajima,Y. Nakajima

DOI: https://doi.org/10.1073/PNAS.93.25.14917

1996-12-10

Abstract:Slow nonselective cation conductances play a central role in determining the excitability of many neurons, but heretofore this channel type has not been analyzed at the single-channel level. Neurotensin (NT) excites cultured dopaminergic neurons from the ventral tegmental area primarily by increasing such a cation conductance. Using the outside-out configuration of the patch clamp, we elicited single-channel activity of this NT-induced cation channel. Channel activity was blocked by the nonpeptide NT antagonist SR48692, indicating that the response was mediated by NT receptors. The channel opened in both solitary form and in bursts. The reversal potential was -4.2 +/- 1.7 mV, and the elementary conductance was 31 pS at -67 mV with [Na+]o = 140 mM, [Cs+]o = 5 mM, [Na+]i = 88 mM, and [Cs+]i = 74 mM. Thus, the channel was permeable to both Na+ and Cs+. From these characteristics, it is likely that this channel is responsible for the whole-cell current we studied previously. In guanosine 5'-[gamma-thio]triphosphate-loaded cells, NT irreversibly activated about half of the channel activity, suggesting that at least part of the response was mediated by a G protein. Similar channel activity could be induced occasionally in the cell-attached configuration by applying NT outside the patch region.
Abstract IA023: Spatial reconstruction and temporal inference of DNA methylation alterations in primary human colorectal cancer

Peter W. Laird,Nathan J. Spix,Hsiao-yun Milliron,Manpreet Kalkat,Emily Eugster,David Sokol,Emily Jung,Paula Nolte,Kelly K. Krzyzanowski,Toshinori Hinoue,Hui Shen

DOI: https://doi.org/10.1158/1538-7445.canevol23-ia023

IF: 11.2

2024-02-02

Cancer Research

Abstract:Phenotypic plasticity is thought to assist immune evasion, metastasis, and therapeutic resistance in tumor evolution. Epigenetic mechanisms such as DNA methylation provide for a more easily acquired and flexible, yet semi-stable adaptation by the tumor cell than hardwired genetic changes. Cancer-associated gain of DNA methylation at promoter CpG islands or distal regulatory elements is associated with transcriptional silencing, whereas loss of DNA methylation is observed at late-replicating, lamina-attached regions of the genome, tracking with cumulative cell divisions. One of the most well-documented genomic features predisposing to DNA hypermethylation is Polycomb Repressive Complex (PRC) occupancy in precursor cells, consistent with an epigenetic block to cellular differentiation as an early or predisposing event in carcinogenesis. A central question is whether this epigenetic switch from reversible PRC repression to more stable DNA hypermethylation occurs before onset of clonal expansion, or whether it represents an ongoing process during tumor evolution. Clonal expansion is a pivotal characteristic of cancer, and is thought to be initiated by a genetic alteration in a key gatekeeper driver gene. However, not all normal cells appear to be susceptible to malignant transformation following such an event. Multiple lines of evidence suggest that epigenetic heterogeneity among normal cells may affect their cancer-initiating potential. We have developed a tumor processing pipeline to deeply and comprehensively map DNA methylation patterns in primary human colorectal cancer (CRC) and adjacent tissues, while preserving spatial information, enabling inference of the temporal order of molecular alterations. We employ a suite of technologies to map the spatial heterogeneity of DNA methylation patterns in primary human CRC. These include a deep single-cell whole-genome bisulfite sequencing technique that improves genomic coverage several-fold over existing published protocols, providing DNA methylation measurements at the majority of CpGs in the genome in individual tumor cells. We have also calibrated and validated an epigenetic clock that allows us to accurately measure the relative replicative history of individual cells. We infer phylogenetic relationships among subclones, and relate these to their spatial distribution in the primary tumor. We find that some tumors have high proportions of PRC-associated clonal hypermethylation, indicating that these hypermethylation events were already present prior to clonal expansion, possibly contributing to susceptibility to malignant transformation in the cell-of-origin, whereas other tumors appear to have active PRC-associated CpG island hypermethylation ongoing during tumor expansion, generating subclonal heterogeneity, which may influence post-therapeutic recurrence potential. Citation Format: Peter W. Laird, Nathan J. Spix, Hsiao-yun Milliron, Manpreet Kalkat, Emily Eugster, David Sokol, Emily Jung, Paula Nolte, Kelly K. Krzyzanowski, Toshinori Hinoue, Hui Shen. Spatial reconstruction and temporal inference of DNA methylation alterations in primary human colorectal cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2) nr IA023.

oncology
Epigenetic biomarkers of ageing are predictive of mortality risk in a longitudinal clinical cohort of individuals diagnosed with oropharyngeal cancer

Rhona A. Beynon,Suzanne M. Ingle,Ryan Langdon,Margaret May,Andy Ness,Richard M. Martin,Matthew Suderman,Kate Ingarfield,Riccardo E. Marioni,Daniel L. McCartney,Tim Waterboer,Michael Pawlita,Caroline Relton,George Davey Smith,Rebecca C. Richmond

DOI: https://doi.org/10.1186/s13148-021-01220-4

2022-01-03

Clinical Epigenetics

Abstract:Abstract Background Epigenetic clocks are biomarkers of ageing derived from DNA methylation levels at a subset of CpG sites. The difference between age predicted by these clocks and chronological age, termed “epigenetic age acceleration”, has been shown to predict age-related disease and mortality. We aimed to assess the prognostic value of epigenetic age acceleration and a DNA methylation-based mortality risk score with all-cause mortality in a prospective clinical cohort of individuals with head and neck cancer: Head and Neck 5000. We investigated two markers of intrinsic epigenetic age acceleration ( IEAAHorvath and IEAAHannum ), one marker of extrinsic epigenetic age acceleration ( EEAA ), one optimised to predict physiological dysregulation ( AgeAccelPheno ), one optimised to predict lifespan ( AgeAccelGrim ) and a DNA methylation-based predictor of mortality ( ZhangScore ). Cox regression models were first used to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI) for associations of epigenetic age acceleration with all-cause mortality in people with oropharyngeal cancer ( n = 408; 105 deaths). The added prognostic value of epigenetic markers compared to a clinical model including age, sex, TNM stage and HPV status was then evaluated. Results IEAAHannum and AgeAccelGrim were associated with mortality risk after adjustment for clinical and lifestyle factors (HRs per standard deviation [SD] increase in age acceleration = 1.30 [95% CI 1.07, 1.57; p = 0.007] and 1.40 [95% CI 1.06, 1.83; p = 0.016], respectively). There was weak evidence that the addition of AgeAccelGrim to the clinical model improved 3-year mortality prediction (area under the receiver operating characteristic curve: 0.80 vs. 0.77; p value for difference = 0.069). Conclusion In the setting of a large, clinical cohort of individuals with head and neck cancer, our study demonstrates the potential of epigenetic markers of ageing to enhance survival prediction in people with oropharyngeal cancer, beyond established prognostic factors. Our findings have potential uses in both clinical and non-clinical contexts: to aid treatment planning and improve patient stratification.

oncology,genetics & heredity
Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer

Ting Xu,Yinjie Zhang,Jing Zhang,Changsong Qi,Dan Liu,Zhenghang Wang,Yanyan Li,Congcong Ji,Jian Li,Xuan Lin,Ting Hou,Hao Liu,Lu Zhang,Han Han-Zhang,Lin Shen,Xicheng Wang

DOI: https://doi.org/10.3389/fonc.2020.568911

IF: 4.7

2020-10-19

Frontiers in Oncology

Abstract:Background: Early onset colorectal cancer (EO CRC) is a heterogeneous colorectal cancer subtype with obvious hereditary tendencies and increasing incidence. We sought to determine the susceptibility genes and molecular characteristics of EO CRC.Methods: 330 EO metastatic CRC (mCRC) (≤55 years) and 110 average-onset (AO) mCRC patients (>55 years) were enrolled. Capture-based targeted sequencing was performed on tumor tissue and paired white blood cells using a sequencing panel of 520 genes. The association between molecular alterations and overall survival (OS) was analyzed.Results: Of the 330 EO mCRC patients, 31 carried pathogenic or likely pathogenic germline mutations, with 16 of them diagnosed with lynch syndrome. Fifteen patients had germline mutations in non-mismatch repair genes, including four in MUTHY, three in RAD50, one in TP53, and eight in other genes. Twenty-nine genes were recurrently mutated in EO mCRC, including TP53, APC, KRAS, SMAD4, and BRCA2. The majority of genomic alterations were comparable between EO and AO mCRC. EO mCRC patients were more likely to have a high tumor mutation burden (p < 0.05). RNF43, RBM10, TSC, and BRAF V600E mutations were more commonly observed in EO mCRC, while APC, ASXL1, DNMT3B, and MET genes were more commonly altered in AO patients. At the pathway level, the WNT pathway was the only differentially mutated pathway between EO and AO mCRC (p < 0.0001). The wild-type WNT pathway (p = 0.0017) and mutated TGF-β pathway (p = 0.023) were associated with unfavorable OS in EO mCRC.Conclusions: Approximately one in 10 EO mCRC was associated with hereditary tumors. The spectrum of somatic alterations was largely comparable between EO and AO mCRC with several notable differences.

oncology
Deviation from the Precisely Timed Phenomic Ageotypes Can Assist in Early CRC Screening and Reveal Underlying Pathophysiology.

Sheeno P. Thyparambil,Jin You,Kang Liu,Hui Sun,Junjie Peng,Sanjun Cai,Yaqi Li,Chen Fu,Pingping Bao,Qing Li,Shiying Hao,Yani Zhang,Zhen Li,Jingzhi Yang,Ziyu Yin,Xiaoming Yao,Xiurui Zhu,James Schilling,Karl G. Sylvester,Xuefeng B. Ling

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.e16098

IF: 45.3

2020-01-01

Journal of Clinical Oncology

Abstract:e16098 Background: Human serum proteome and metabolome profiles have been analyzed to explore the molecular changes that occur with aging. We hypothesized that deep phenomic profiling of longitudinal sera would allow the identification of distinct phenomic chronologic patterns as a normal biological clock baseline to study personal aging. We further hypothesized that molecular assessment of this chronologic deviation, due to advance adenoma and early CRC, from the normal reference ageotypes would be instrumental as potential early diagnostics and reveal underlying pathophysiology. Methods: A cohort of 7673 normal, 746 advanced adenoma, 1177 stage I, 103 stage II and 119 stage III blood samples were assembled. Innovative multi-omics approaches, with global and targeted LCMS data production (metabolomics, lipidomics, and 2D proteomics), were applied to deep profile these subjects. Identification of the age-associated molecular patterns in normal subjects, modeled with an elastic net algorithm, established the reference baseline to mirror a biological clock. CRC associated deviation from this chronologically paced multi-omics clock was quantified to screen for early CRCs and explore the underlying pathophysiology. Results: Multiple mProbe aging indices of proteins and metabolites were identified, strongly predicting chronologic age ( P < 0.001, R > 0.90). Significant disruptions from normal molecular patterns were observed in advanced adenoma and early CRCs patients (R < 0.7). Pathway analysis of the proteins/metabolites with deviating patterns revealed both known and new pathways underlying CRC. Unsupervised cluster analysis identified unique aging subgroups among advanced adenoma and different stage CRC patients, indicating unique underlying biology relating to aging with different severities of cancer burdens. Conclusions: Deviations from the meticulously timed phenomic aging patterns may provide utility to allow future early CRC screening. Close examination of the underlying pathophysiology associated with early CRC, relating to ageotypes, not only may improve the sensitivity and specificity of prognostic and diagnostic tests of early CRCs, but also shed new insights into CRC therapeutics.
Abstract 3439: Factors affecting the performance of existing epigenetic clocks to predict chronological age in colorectal tumor and normal tissues

Christopher L. Benson,Ferran Moratalla-Navarro,Anna Diez-Villanueva,Matthew A. Devall,Victor Moreno,Stephanie L. Schmit,Fredrick R. Schumacher

DOI: https://doi.org/10.1158/1538-7445.am2024-3439

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Epigenetic age (EA) may serve as a risk stratification biomarker for early-onset colorectal cancer (EOCRC, <50 years old), which has been rising substantially in recent decades. We utilized publicly available data in a descriptive analysis to compare epigenetic clocks in colorectal tissue and to investigate differences between chronological age (CA) and biological age, as measured by EA, in relation to demographic and clinical features. We analyzed DNA methylation (DNAm) array data on 144 participants (96 CRC cases, 48 healthy controls) from the Colonomics Study (CLX; Barcelona, Spain) and 331 CRC cases (51 EOCRC, 316 average-onset (≥50) colorectal cancer (AOCRC)) from The Cancer Genome Atlas (TCGA) as well as corresponding demographic and clinical variables. Among CLX participants, the 96 CRC cases provided colon tumor and paired normal mucosa samples, while the 48 controls provided healthy colon mucosa samples. TCGA included primary tumor samples from 331 cases with colon or rectal adenocarcinoma (TCGA-COADREAD). The 2013 Horvath clock estimated EA based on CA, while epiTOC, estimated the relative stem cell division rate from tissue biospecimens. We examined the correlations between CA and EA stratified by case/control status, sample type, sex, and age of onset (TCGA only). Tissue from CLX controls demonstrated a strong, positive correlation (r>0.9) between CA and EA for both the 2013 Horvath and epiTOC clocks. Using the Horvath clock, CA and EA correlations in normal mucosa and tumor tissue samples from CLX varied, with r = 0.74 and r = 0.41, respectively, and were weaker using the epiTOC clock, with r = 0.26 (normal) and r = 0.10 (tumor). When CLX cases were stratified by sex, the CA and EA (Horvath) correlations among female cases were r = 0.80 (normal) and r = -0.12 (tumor), while the correlations for males were stronger at r = 0.58 (normal) and r = 0.31 (tumor). This is in comparison to the epiTOC clock with females showing correlations of r = -0.02 (normal) and r = 0.41 (tumor), while males had r = 0.06 (normal) and r = 0.11 (tumor). In TCGA, correlations for EOCRC were r = -0.20 (Horvath) and r = -0.08 (epiTOC) and for AOCRC were r = 0.29 and 0.20, respectively. By sex, correlations for females with EOCRC for Horvath and epiTOC were r = -0.09 and r = -0.07, respectively, while correlations for males with EOCRC were r = -0.02 and r = -0.08, respectively. For TCGA cases with AOCRC, the correlations between CA and EA were r = 0.35 and r = 0.22 for females, and r = 0.26 and r = 0.20 for males, respectively for Horvath and epiTOC. This study revealed substantial variability in the ability of existing epigenetic clocks to accurately predict chronological age, with tissue type and sex strongly influencing the resulting correlations. Our findings highlight the importance of considering these factors when choosing an epigenetic clock. Citation Format: Christopher L. Benson, Ferran Moratalla-Navarro, Anna Diez-Villanueva, Matthew A. Devall, Victor Moreno, Stephanie L. Schmit, Fredrick R. Schumacher. Factors affecting the performance of existing epigenetic clocks to predict chronological age in colorectal tumor and normal tissues [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3439.

oncology

Evidence-based practices need to beware of experts.

Evidence of Accelerated Epigenetic Aging of Breast Tissues in Patients with Breast Cancer is Driven by CpGs Associated with Polycomb Related Genes

Abstract 7005: Distinct DNA methylation patterns between early-onset and average-onset colorectal cancer patients

Abstract P2-09-02: Evidence of Accelerated Epigenetic Aging of Breast Tissues in Patients with Breast Cancer Compared to Women Without Cancer

Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer

Aging related methylation influences the gene expression of key control genes in colorectal cancer and adenoma

Abstract 7017: Increased epigenetic age acceleration in young adult and early onset colorectal cancer patients post-treatment: A ColoCare Pilot Study

DNA methylation age as a biomarker for cancer

Epigenetic age acceleration of cervical squamous cell carcinoma converged to human papillomavirus 16/18 expression, immunoactivation, and favourable prognosis

Genomic landscape of diploid and aneuploid microsatellite stable early onset colorectal cancer

Tumor Long Interspersed Nucleotide Element-1 (LINE-1) Hypomethylation in Relation to Age of Colorectal Cancer Diagnosis and Prognosis

DNA methylation-based biological aging and cancer risk and survival: Pooled analysis of seven prospective studies

DNA Methylation Age in Paired Tumor and Adjacent Normal Breast Tissue in Chinese Women with Breast Cancer

Epigenome-wide Gene–age Interaction Analysis Reveals Reversed Effects of PRODH DNA Methylation on Survival Between Young and Elderly Early-Stage NSCLC Patients

Exploring the DNA methylome of Korean patients with colorectal cancer consolidates the clinical implications of cancer-associated methylation markers

Single-channel properties of the nonselective cation conductance induced by neurotensin in dopaminergic neurons.

Abstract IA023: Spatial reconstruction and temporal inference of DNA methylation alterations in primary human colorectal cancer

Epigenetic biomarkers of ageing are predictive of mortality risk in a longitudinal clinical cohort of individuals diagnosed with oropharyngeal cancer

Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer

Deviation from the Precisely Timed Phenomic Ageotypes Can Assist in Early CRC Screening and Reveal Underlying Pathophysiology.

Abstract 3439: Factors affecting the performance of existing epigenetic clocks to predict chronological age in colorectal tumor and normal tissues